It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings ...

Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...

We recently compiled a list of the 11 Most Expensive Stocks Insiders Are Buying Recently. In this article, we are going to ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class ...

UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

Donald Trump has instructed pharmaceutical companies to relocate their production to the United States, warning they could ...

Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth.

The S&P500 (SP500) closed in the red on Friday, after the week saw dour economic reports, headlines on U.S. President Donald Trump’s tariff policy and corporate earnings from firms including Walmart ...